The Clinical Trial Company (TCTC), a niche contract research organisation (CRO) formed in the UK in 2002, has launched The Clinical Trial Company (USA) Inc to address its growing roster of US clients and study sponsors.
As well as incorporating its new US business, TCTC has opened a West Coast office in the San Francisco Bay area to supplement its existing North American presence in Montreal, Canada.
The US expansion means the company now has group headquarters in Knutsford, Cheshire, along with offices in San Mateo (US), Berlin (Germany), Montreal (Canada) and Sydney (Australia).
The US business is being led by David W J Smith, who has “extensive” experience of building new healthcare businesses in Europe and the US over the past 25 years, TCTC said.
Quick and effective
With fewer funding sources available to pharmaceutical and device companies, it is increasingly important for these companies to invest their money wisely and execute clinical strategies as quickly and effectively as possible, Smith pointed out.
“TCTC has a great track record of doing this for clients in Europe and Canada and I am delighted to join the team to continue that success in the US,” he commented.
The company was set up with a focus on medium-size clinical trials and innovative products that lack a “classical road map” to market.
TCTC specialises in advanced-therapy drugs, such as cell and gene therapy, as well as first-in-class biotechnology products. Often these are orphan drugs addressing the unmet clinical needs of rare diseases.
